Ovation Pharmaceuticals
Deerfield
About Ovation Pharmaceuticals
Ovation Pharmaceuticals was acquired by [Lundbeck., Inc.](/organization/lundbeck), in March 2009. The company was founded in 2000, and as of its acquisition in 2009 it operates as a subsidiary of H. Lundbeck A/S. Lundbeck, Inc., a biopharmaceutical company, engages in developing, manufacturing, and selling pharmaceutical products primarily in the United States. Its products include methamphetamine hydrochloride tablets, mephobarbital tablets, pentobarbital sodium injections, ethotoin tablets, and clorazepate dipotassium and tetrabenazine tablets. The company’s products also include antithrombin, dactinomycin, asparaginase, mechlorethamine, and hemin injections; and succimer, benztropine mesylate, indomethacin, and ibuprofen lysine injections. In addition, Lundbeck offers Sabril (vigabatrin) tablets and powder for oral solutions. Its products are used for central nervous system, hematology, and oncology-related diseases and disorders, as well as used in hospitals. The company markets its products in Argentina, Brazil, Canada, Costa Rica, Guatemala, Honduras, Mexico, Australia, Hong Kong, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, Austria, Belgium, Bulgaria, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, the United Kingdom, and Israel.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 5,001 – 10,000
- Website: ovationpharma.com
- Phone: 800-455-1141
Social Profiles
Canonical: https://fsome.com/organization/ovation-pharmaceuticals-2898276 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.